The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Additionally, by the fourth week of the study, 22.5% of participants taking 84 milligram (mg) doses of Spravato achieved MDD remission with an MADRS total score of less than or equal to 12 ...

WEST HARTFORD, CT (WFSB) – A man was killed in a two-vehicle crash on Interstate 84 in West Hartford early Monday morning. State police identified the man as 30-year-old Tamek Nelson Skinner of ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat. The United States Food and Drug Administration (FDA ...

Police said the woman died at a property on Kingsbury Avenue, Dunstable An 83-year-old man has been charged with the murder of a woman, 84, who was found dead in her home. Bedfordshire Police ...

According to reports, the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression in the 2019 however, this was only allowed as a prescription ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression. Currently, the Food and Drug Administration (FDA) only approves ketamine for use as ...